AAKAAR (AAKAAR) fundamentals
AAKAAR is a listed company, part of the Healthcare sector, listed on the NSE as AAKAAR (ISIN INE1GYP01013). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What AAKAAR does
Aakaar Medical Technologies Limited is an India-based medical aesthetic company. The Company deals in a range of aesthetic & specialized cosmetic products & devices. Its product range includes both its own brands (domestically manufactured products & internationally manufactured devices) and imported brands (distribution of imported brands) from countries such as Korea, Spain, Italy, and Austria. It supplies its products and devices primarily to dermatologists, plastic surgeons, and aesthetic physicians, who then sell these products to their end consumers as well as use certain device consumables as part of their treatments. Its products include Lytec Cream, Lytec Gluta, Lytec HYDRA, Lytec Nano C20, Lytec Klense, Lytec SHELL SUNSCREEN, MELINE 02 Dark Circles, MELINE 00 PREP, MELINE 01 Dark Circles, MELINE 01 Ethnic Skin, MELINE 01 ID, MELINE 01 INTIMATE, MELINE 05 PIGMENT HOME MASK, Swyada Snail Mask, Theraderm Aloe soothing complex, TUBELiTE Gold, Regenera Activa AMT, and others.
Valuation and market data
| Last close | ₹63.00 |
|---|---|
| Market capitalisation | ₹84 crore |
| Enterprise value | ₹69 crore |
| P/E (TTM) | 3.79 |
| Price to book | 1.54 |
| Price to sales (TTM) | 0.40 |
| Book value per share | ₹40.99 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹68 crore | ₹9 crore | ₹7 crore | 4.99 |
| Mar 2025 | ₹62 crore | ₹8 crore | ₹6 crore | 6.12 |
| Mar 2024 | ₹46 crore | ₹4 crore | ₹3 crore | 3.15 |
| Mar 2023 | ₹33 crore | ₹3 crore | ₹2 crore | 2.37 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Mar 2026:
| Promoters | 67.0% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 11.2% |
| Retail and others | 21.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.